Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

BE SURE enrolled 478 participants with chronic plaque psoriasis for at least six months prior to screening and with an affected body surface ... clinical studies. The full BE SURE results will ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

Relative to psoriasis in other areas of the body, genital psoriasis also has a ... for ZORYVE to advance the standard of care in plaque psoriasis, atopic dermatitis and seborrheic dermatitis.

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

On May 19, she shared an Instagram video of an easy full-body yoga workout, breaking down each exercise she did, and also listed their benefits. Malaika Arora does the Hatha Surya Namaskara yoga ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.